Regenxbio Inc (RGNX)

Financial leverage ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Total assets	US$ in thousands	573,970	633,786	682,458	747,830	833,268	883,793	953,444	1,025,370	1,113,900	800,395	836,402	879,442	708,164	541,174	449,738	463,936	497,908	509,237	529,139	519,031
Total stockholders’ equity	US$ in thousands	311,742	363,100	405,855	465,139	516,195	563,824	630,519	689,669	764,298	461,414	507,245	554,504	377,753	415,660	397,861	420,152	450,197	468,395	494,592	487,053
Financial leverage ratio		1.84	1.75	1.68	1.61	1.61	1.57	1.51	1.49	1.46	1.73	1.65	1.59	1.87	1.30	1.13	1.10	1.11	1.09	1.07	1.07

December 31, 2023 calculation

Financial leverage ratio = Total assets ÷ Total stockholders’ equity
= $573,970K ÷ $311,742K
= 1.84

Regenxbio Inc's financial leverage ratio has been gradually trending upwards over the past eight quarters, indicating an increase in the company's level of financial leverage. The ratio has moved from 1.49 in Q1 2022 to 1.84 in Q4 2023, reflecting a consistent rise over this period. This suggests that the company has been relying more on debt financing relative to equity to fund its operations and growth initiatives.

A financial leverage ratio above 1 indicates that the company is primarily financed by debt, which can magnify returns on equity but also increase financial risk. Regenxbio's increasing ratio may imply that it is taking on more debt to support its expansion or investment activities. Investors and analysts typically monitor changes in the financial leverage ratio as it can impact the company's profitability, solvency, and overall financial health.